[go: up one dir, main page]

KR870001198A - 헤테로환 화합물의 제조방법 - Google Patents

헤테로환 화합물의 제조방법 Download PDF

Info

Publication number
KR870001198A
KR870001198A KR1019860006010A KR860006010A KR870001198A KR 870001198 A KR870001198 A KR 870001198A KR 1019860006010 A KR1019860006010 A KR 1019860006010A KR 860006010 A KR860006010 A KR 860006010A KR 870001198 A KR870001198 A KR 870001198A
Authority
KR
South Korea
Prior art keywords
compound
formula
methyl
salt
group
Prior art date
Application number
KR1019860006010A
Other languages
English (en)
Other versions
KR920001670B1 (ko
Inventor
윌리암 옥스포드 알렉산더
데이비드 엘드레드 콜린
해롤드 코우츠 아이안
앤거스 벨 제임스
세드릭 훔버 데이비드
블랜취 에완 조오지
Original Assignee
배리 안토니 뉴샘
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 배리 안토니 뉴샘, 글락소 그룹 리미티드 filed Critical 배리 안토니 뉴샘
Publication of KR870001198A publication Critical patent/KR870001198A/ko
Application granted granted Critical
Publication of KR920001670B1 publication Critical patent/KR920001670B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

내용 없음.

Description

헤테로환 화합물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 다음 구조식(II)의 화합물 또는 그의 염 또는 보호된 유도체를 환화반응시키는 것을 특징으로 하는 다음 구조식(I)의 헤테로환 화합물 또는 그의 염 또는 보호된 유도체의 제조방법.
    위 각 식에서, R1은 수소원자 또는 C1-10알킬기, C3-7시클로알킬기, C3-7시클로알킬-(C1-4)알킬기, C3-6알케닐기, C3-10알키닐기, 페닐기 또는 페닐-(C1-3) 알킬기이고, R2, R3및 R4로 나타내는 기들중의 하나는 수소 원자 또는 C1-6알킬기, C3-7시클로알킬기, C2-6알케닐기 또는 페닐-(C1-3)알킬기이고, 다른 두 개의 기의 각각은 동일 또는 상이한 것으로서, 수소원자 또는 C1-6알킬기이다.
  2. 제1항에 있어서, 구조식(I)의 화합물이 보호된 유도체의 형태로 생성되고, 이어서 보호기 또는 보호기들은 제거되어 구조식(I)의 화합물을 생성하며, 또한 구조식(I)의 화합물이 유리 염기형태로 생성되고, 이어서 유리염기는 염으로 전환되는 것이 특징인 방법.
  3. 제1항 또는 제2항에 있어서, 환화 반응이 산촉매의 존재하에 수성 또는 비수성 매질내에서 수행되는 것이 특징인 방법.
  4. 제1항 또는 제2항에 있어서, 환화반응이 루이스산 촉매 존재하에 무수반응 매질내에서 수행되는 것이 특징인 방법.
  5. 제4항에 있어서, 무수반응 매질이 알콜, 에테르, 카르복실산 또는 에스테르의 1종 이상으로 이루어진 것이 특징인 방법.
  6. 제1항 내지 제5항중 어느 하나의 항에 있어서, 구조식(I)의 화합물이 다음 구조식(III)의 화합물 또는 그의 염을 다음 구조식(IV)의 화합물 또는 그의 염 또는 보호된 유도체와 반응시켜 직접 제조하는 것이 특징인 방법.
    위 각 식에서 R1, R2, R3및 R4는 제1항에서 정의한 바와 같다.
  7. 제1항 내지 제5항중 어느 하나의 항에 있어서, 구조식(II)의 화합물이 다음 구조식(III)의 화합물 또는 그의 염을 다음 구조식(IV)의 화합물 또는 그의 염 또는 보호된 유도체와 반응시키는 것이 특징인 방법.
    위 각 식에서 R1, R2, R3및 R4는 제1항에서 정의한 바와 같다.
  8. 제7항에 있어서, 구조식(III)의 화합물 또는 그의 염과 구조식(IV)의 화합물 또는 그의 보호된 유도체간의 반응이 20 내지 100℃의 온도에서 물 또는 알콜수용액에서 수행되는 것이 특징인 방법.
  9. 제1항 내지 제8항중 어느 하나의 항에 있어서, R1이 수소원자 또는 C1-10알킬기, C3-7시클로알킬기, C3-6알케닐기, 페닐기 또는 페닐-(C1-3)알킬기이고, R2, R3및 R4가 제1항에 정의한 바와같은 구조식(I)의 화합물 또는 약리학적으로 허용되는 그의 염 또는 용매화물이 제조되는 것이 특징인 방법.
  10. 제1항 내지 제8항중 어느 하나의 항에 있어서, 1,2,3,9-테트라히드로-3-[(2-메틸-1H-이미다졸-1-일)메틸]-9-(2-프로페닐)-4H-카르바졸-4-온, 9-시클로페닐-1,2,3,9-테트라히드로-3-[(2-메틸-1H-이미다졸-1-일)메틸]-4H-카르바졸-4-온, 1,2,3,9-테트라히드로-9-(1-메틸에틸)-3-[(2-메틸-1H-이미다졸-1-일)메틸]-4H-카르바놀-4-온과 약리학적으로 허용되는 이들의 염 및 용매화물이 제조되는 것이 특징인 방법.
  11. 제1항 내지 제8항중 어느 하나의 항에 있어서 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1H-이미다졸-1-일)메틸]-4H-카르바졸-4-온 또는 약리학적으로 허용되는 그의 염 또는 용매화물이 제조되는 것이 특징인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860006010A 1985-07-24 1986-07-24 헤테로환 화합물의 제조방법 KR920001670B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8518741 1985-07-24
GB858518741A GB8518741D0 (en) 1985-07-24 1985-07-24 Process

Publications (2)

Publication Number Publication Date
KR870001198A true KR870001198A (ko) 1987-03-12
KR920001670B1 KR920001670B1 (ko) 1992-02-22

Family

ID=10582813

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860006010A KR920001670B1 (ko) 1985-07-24 1986-07-24 헤테로환 화합물의 제조방법

Country Status (12)

Country Link
US (1) US4739072A (ko)
EP (1) EP0219929B1 (ko)
JP (1) JPH07612B2 (ko)
KR (1) KR920001670B1 (ko)
AT (1) ATE73451T1 (ko)
CA (1) CA1281722C (ko)
DE (1) DE3684225D1 (ko)
ES (1) ES2000935A6 (ko)
FI (1) FI84350C (ko)
GB (1) GB8518741D0 (ko)
GR (1) GR861926B (ko)
PT (1) PT83043B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617994D0 (en) * 1986-07-23 1986-08-28 Glaxo Group Ltd Heterocyclic compounds
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
US5360800A (en) * 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
JPH01258673A (ja) * 1987-10-22 1989-10-16 Glaxo Group Ltd ケトン誘導体
US5225431A (en) * 1987-10-23 1993-07-06 Burroughs Wellcome Co. Therapeutic substituted indole compounds and compositions thereof
US5008272A (en) * 1988-08-15 1991-04-16 Glaxo Group Limited Lactam derivatives
DE69004924T2 (de) 1989-04-21 1994-05-19 Sandoz Ag Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
ES2043535B1 (es) * 1992-03-13 1994-08-01 Vita Invest Sa Procedimiento para la obtencion de la 1,2,3,9-tetrahidro-9-metil-3-(2-metil-1h-imidazol-1-il)metil*-4h-carbazol-4-ona.
HU212934B (en) 1992-10-14 1996-12-30 Richter Gedeon Vegyeszet Process for producing novel alkoxalylated carbazolone derivatives
ES2204358T1 (es) * 2000-10-30 2004-05-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion.
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
MXPA04010846A (es) * 2002-04-29 2005-01-25 Biogal Gyogyszergyar Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona.
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20090170872A1 (en) * 2005-07-05 2009-07-02 Orchid Research Laboratories Limited Compounds and Their Pharmaceutical Use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
US3892766A (en) * 1974-06-03 1975-07-01 Warner Lambert Co Process for the preparation of 4-keto-1,2,3,4-tetrahydrocarbazole
GR73560B (ko) * 1979-02-24 1984-03-15 Pfizer
EP0073849A1 (en) * 1981-09-03 1983-03-16 Schering Corporation Novel phenyl-1,2,3,4-tetrahydrocarbazoles, their preparation and pharmaceutical compositions containing them
DE19375046I2 (de) * 1984-01-25 2002-10-10 Glaxo Group Ltd 1,2,3,9-Tetrahydro-3-Ä(1H-imidazol-1-yl)methylÜ-4H-carbazol-4-one Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
ES2000935A6 (es) 1988-04-01
FI863019L (fi) 1987-01-25
CA1281722C (en) 1991-03-19
FI863019A0 (fi) 1986-07-23
ATE73451T1 (de) 1992-03-15
US4739072A (en) 1988-04-19
FI84350B (fi) 1991-08-15
EP0219929A1 (en) 1987-04-29
FI84350C (fi) 1991-11-25
JPS6277380A (ja) 1987-04-09
KR920001670B1 (ko) 1992-02-22
DE3684225D1 (de) 1992-04-16
PT83043A (en) 1986-08-01
PT83043B (pt) 1989-02-28
EP0219929B1 (en) 1992-03-11
JPH07612B2 (ja) 1995-01-11
GB8518741D0 (en) 1985-08-29
GR861926B (en) 1986-09-05

Similar Documents

Publication Publication Date Title
KR870001198A (ko) 헤테로환 화합물의 제조방법
IE791565L (en) Crop cutting apparatus
GB1379790A (en) Process for producing 7-acylamido-3-cephem-4-carboxylic acids
KR860005794A (ko) 이미다졸 유도체의 제조방법
GB753919A (en) Improvements relating to derivatives of 2-aryl indoles and of 2-aryl indolines, and their use
EA200000484A1 (ru) Способ получения производных тиазолидиндиона
YU217181A (en) Process for preparing 2-(1,4-benzodioxane-2-ylalkyl)-imidazoles
KR870002069A (ko) 2-(3,5-디알킬-4-히드록시페닐) 인돌 유도체의 제조방법
KR880011122A (ko) 4-티오퀴나졸린 유도체, 이의 제조방법 및 약제학적 조성물
ES8104239A1 (es) Se persona en el expediente el agente que pasa a ser carlos fernandez candelas.
KR830006288A (ko) 카바펜암과 카바펜-2-엠의 제조방법
KR910000652A (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
KR920021527A (ko) 신규 2-피페라지닐벤즈이미다졸 유도체 및 그 제조 방법
DE3677857D1 (de) 2,5-dimethylpyrrolderivative, ihre herstellung und ihre verwendung.
CA1268183A (en) INTERMEDIATES OF PHOSPHORANE USED IN THE PREPARATION OF ANTIBIOTIC PENEMS
IE792508L (en) Piperidylindoles
ATE8257T1 (de) Verfahren zur herstellung von 4-chinolinonen.
KR890002174A (ko) 삼환성 세팜 화합물, 그의 제조방법 및 용도
KR870010043A (ko) 헤테로고리로 치환된 벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 제약조성물
KR840007411A (ko) β-락탐 화합물의 제조방법
KR880011141A (ko) 신규한 화합물
KR950704289A (ko) α-아릴-r-부티로락톤의 제조방법(Process for the preparation of α-aryl-r-butyrolactones)
ES8703475A1 (es) Un procedimiento para la preparacion de derivados de 5-cetomilbemicina.
GB745495A (en) Improvements in or relating to 4-substituted amino-5-hydroxy-benz(cd)-indoles and their acid addition salts and process of preparing the same
ES440270A1 (es) Procedimiento para preparar imidas de esteres de acidos n- (aminometiliden)-tiolfosforicos y tionofosforicos.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19860724

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19891220

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19860724

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19910730

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19920124

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19920512

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19920702

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19920702

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19950220

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19960216

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19970221

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19970830

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19990211

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20000215

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20010215

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20020214

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20030206

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20040112

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20050107

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20060106

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20060106

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term